Egrifta (Tesamorelin Acetate) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Egrifta (Tesamorelin Acetate) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as increased awareness of HIV-related complications, rising demand for drug therapy, greater use of antiretroviral therapy, a growing focus on quality of life, advancements in medical research, and heightened awareness.

Market growth during the forecast period is expected to be driven by the increasing prevalence of chronic diseases, the rising number of hospitals, greater demand for advanced body health monitoring tools, a higher incidence of metabolic disorders, and growing awareness of disease treatment options. Key trends for this period include the increasing adoption of targeted treatments, integration with comprehensive care plans, expansion of personalized medicine, enhanced patient support programs, and a rise in research activities.

The growing prevalence of HIV cases is significantly contributing to the expansion of the egrifta (tesamorelin acetate) market. HIV refers to a condition where individuals become infected with the virus, leading to the gradual weakening of their immune system. The increase in HIV cases can be attributed to a lack of awareness and education on preventive measures, such as the use of condoms and regular testing, especially among high-risk groups. Egrifta works by stimulating the release of growth hormone, which helps reduce excess visceral fat and improve body composition, ultimately enhancing the health and quality of life of people living with HIV. For example, in May 2024, the Minnesota Department of Health reported that 324 new HIV diagnoses were made in 2023, reflecting a 24% increase from the previous year. As a result, the rising number of HIV cases is driving growth in the egrifta (tesamorelin acetate) market.

A major trend in the egrifta (tesamorelin acetate) market is the development of advanced synthetic peptide drugs aimed at improving the treatment of HIV-related lipodystrophy. These synthetic peptides are designed to mimic or enhance the effects of naturally occurring peptides to deliver specific therapeutic benefits. In December 2024, Theratechnologies Inc., a biopharmaceutical company based in Canada, announced the resumption of EGRIFTA SV production after a temporary shutdown of its contract manufacturer's facility due to FDA inspection findings. The newly manufactured batch has passed quality control and will be released upon approval of a prior approval supplement from the U.S. Food and Drug Administration (FDA). Two additional batches are also in production. The company is managing inventory to meet patient demand until mid-January 2025 and is collaborating with the FDA to avoid a shortage in 2025. EGRIFTA SV is exclusively distributed in the United States.

In January 2023, the World Orphan Drug Alliance (WODA), a Slovenia-based organization that works to improve access to treatments for rare diseases, formed a significant partnership with Theratechnologies to distribute EGRIFTA SV, a medication used to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy. This collaboration aims to improve the availability and accessibility of EGRIFTA SV, which is essential for patients dealing with these conditions. Theratechnologies Inc. is the manufacturer of egrifta (tesamorelin acetate), based in Canada.

The key company operating in the egrifta (tesamorelin acetate) market is Theratechnologies Inc.

North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in egrifta (tesamorelin acetate) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the egrifta (tesamorelin acetate) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Egrifta (tesamorelin acetate) is a synthetic peptide that helps reduce excess abdominal fat in HIV patients with lipodystrophy by stimulating the release of growth hormone. It functions as a growth hormone-releasing hormone (GHRH) analog, targeting and reducing visceral fat. By promoting the breakdown of fat, it helps improve fat distribution and lowers health risks associated with abdominal fat.

The primary clinical indications for egrifta (tesamorelin acetate) include HIV-associated lipodystrophy, growth hormone deficiency, abdominal obesity, and metabolic syndrome. HIV-associated lipodystrophy is a condition in individuals with HIV that results in abnormal fat distribution, such as fat loss in the limbs and excessive fat accumulation in the abdomen. Egrifta is distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks, and is used by various end users, including hospitals, specialized clinics, and home care settings.

The egrifta (tesamorelin acetate) market research report is one of a series of new reports that provides egrifta (tesamorelin acetate) market statistics, including the egrifta (tesamorelin acetate) industry global market size, regional shares, competitors with the egrifta (tesamorelin acetate) market share, detailed egrifta (tesamorelin acetate) market segments, market trends, and opportunities, and any further data you may need to thrive in the egrifta (tesamorelin acetate) industry. This egrifta (tesamorelin acetate) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The egrifta (tesamorelin acetate) market consists of sales of tesamorelin acetate injections and tesamorelin acetate vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.